Celltrion Healthcare (KOSDAQ:A091990) - Share price, News & Analysis

A091990 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

A091990 Stock Overview

Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world.

Rewards

Trading at 53% below our estimate of its fair value

Earnings are forecast to grow 29.41% per year

Risk Analysis

Profit margins (8.5%) are lower than last year (14.8%)

Celltrion Healthcare Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Celltrion Healthcare
Historical stock prices
Current Share Price	₩54,700.00
52 Week High	₩123,333.33
52 Week Low	₩53,800.00
Beta	0.80
1 Month Change	-11.20%
3 Month Change	-13.59%
1 Year Change	-50.97%
3 Year Change	-11.60%
5 Year Change	n/a
Change since IPO	23.60%

Shareholder Returns

	A091990	KR Healthcare	KR Market
7D	-8.8%	-4.6%	-1.8%
1Y	-51.0%	-43.5%	-15.2%

Return vs Industry: A091990 underperformed the KR Healthcare industry which returned -43.5% over the past year.

Return vs Market: A091990 underperformed the KR Market which returned -15.2% over the past year.

Price Volatility

Is A091990's price volatile compared to industry and market?
A091990 volatility
A091990 Average Weekly Movement	6.2%
Healthcare Industry Average Movement	5.7%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: A091990 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: A091990's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1999	131	Hyoung Ki Kim	https://www.celltrionhealthcare.com

Celltrion Healthcare Co., Ltd. engages in the manufacture, processing, and sale of biosimilar and biological medicines to patients around the world. Its products include Remsima, a monoclonal antibody biosimilar that is used for rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn's disease, Crohn's disease in children, psoriasis, and psoriatic arthritis; Truxima, which is used for lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis and microscopic polyangiitis, and rheumatoid arthritis; Herzuma that is used for metastatic breast cancer, early breast cancer, and metastatic gastric cancer; and Remsima SC, which is used for rheumatoid arthritis. The company was formerly known as Nexol, Inc. and changed its name to Celltrion Healthcare Co., Ltd.

Celltrion Healthcare Fundamentals Summary

How do Celltrion Healthcare's earnings and revenue compare to its market cap?
A091990 fundamental statistics
Market Cap	₩8.52t
Earnings (TTM)	₩152.57b
Revenue (TTM)	₩1.80t

55.8x

P/E Ratio

4.7x

P/S Ratio

Is A091990 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A091990 income statement (TTM)
Revenue	₩1.80t
Cost of Revenue	₩1.37t
Gross Profit	₩430.50b
Other Expenses	₩277.93b
Earnings	₩152.57b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	979.54
Gross Margin	23.86%
Net Profit Margin	8.45%
Debt/Equity Ratio	18.9%

How did A091990 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

26%

Payout Ratio

Valuation

Is Celltrion Healthcare undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: A091990 (₩54700) is trading below our estimate of fair value (₩116277.98)

Significantly Below Fair Value: A091990 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: A091990 is poor value based on its PE Ratio (55.8x) compared to the Asian Healthcare industry average (18.1x).

PE vs Market: A091990 is poor value based on its PE Ratio (55.8x) compared to the KR market (14.1x).

Price to Earnings Growth Ratio

PEG Ratio: A091990 is poor value based on its PEG Ratio (1.9x)

Price to Book Ratio

PB vs Industry: A091990 is overvalued based on its PB Ratio (4x) compared to the KR Healthcare industry average (2.2x).

Future Growth

How is Celltrion Healthcare forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

29.4%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A091990's forecast earnings growth (29.4% per year) is above the savings rate (3.5%).

Earnings vs Market: A091990's earnings (29.4% per year) are forecast to grow faster than the KR market (14.8% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A091990's revenue (13.2% per year) is forecast to grow faster than the KR market (9.6% per year).

High Growth Revenue: A091990's revenue (13.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A091990's Return on Equity is forecast to be low in 3 years time (13.8%).

Past Performance

How has Celltrion Healthcare performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

10.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A091990 has high quality earnings.

Growing Profit Margin: A091990's current net profit margins (8.5%) are lower than last year (14.8%).

Past Earnings Growth Analysis

Earnings Trend: A091990's earnings have grown by 10% per year over the past 5 years.

Accelerating Growth: A091990's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A091990 had negative earnings growth (-36.5%) over the past year, making it difficult to compare to the Healthcare industry average (34.1%).

Return on Equity

High ROE: A091990's Return on Equity (7.2%) is considered low.

Financial Health

How is Celltrion Healthcare's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: A091990's short term assets (₩3,702.7B) exceed its short term liabilities (₩1,644.2B).

Long Term Liabilities: A091990's short term assets (₩3,702.7B) exceed its long term liabilities (₩164.7B).

Debt to Equity History and Analysis

Debt Level: A091990 has more cash than its total debt.

Reducing Debt: A091990's debt to equity ratio has reduced from 34.1% to 18.9% over the past 5 years.

Debt Coverage: A091990's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: A091990's interest payments on its debt are well covered by EBIT (20.7x coverage).

Balance Sheet

Dividend

What is Celltrion Healthcare current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

0.46%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: A091990's dividend (0.47%) isn’t notable compared to the bottom 25% of dividend payers in the KR market (0.85%).

High Dividend: A091990's dividend (0.47%) is low compared to the top 25% of dividend payers in the KR market (2.76%).

Stability and Growth of Payments

Stable Dividend: A091990 is not paying a notable dividend for the KR market, therefore no need to check if payments are stable.

Growing Dividend: A091990 is not paying a notable dividend for the KR market, therefore no need to check if payments are increasing.

Earnings Payout to Shareholders

Earnings Coverage: A091990 is not paying a notable dividend for the KR market.

Cash Payout to Shareholders

Cash Flow Coverage: A091990 is paying a dividend but the company has no free cash flows.

Next Steps

Explore strong dividend paying companies in the Healthcare industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Hyoung Ki Kim

no data

Tenure

Hyoung Ki Kim is CEO & Executive Director of Celltrion Healthcare Co., Ltd.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/14 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31